HOUSTON, TX & SEATTLE, WA — Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and other immune-mediated diseases, today announced that the U.S. FDA has granted Fast Track designation for its lead clinical program, IDP-023, for the treatment of patients...
Latest News
InDex Pharmaceuticals Holding AB (publ) announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe...
Solna, Sweden – InDex Pharmaceuticals on Tuesday announced that it is discontinuing the Phase III CONCLUDE program, which was evaluating its investigational immunomodulatory therapeutic cobitolimod in ulcerative colitis. The decision to terminate the late-stage study is in line with the recommendations of an Independent Data Monitoring Committee, which found during...
Bengaluru — The Indian government said on Thursday it was providing a full exemption from basic customs duty for rare disease therapies and Merck & Co Inc’s (MRK.N) cancer therapy Keytruda when such medicines were imported for personal use. The government said in a statement that while some drugs such...
Bengaluru, India – Ovarian cancer is dangerous because it often goes undetected until it has spread beyond the ovaries, and the symptoms can also be attributed to other conditions. Scientists believe that ageing can increase the spread of ovarian and other cancers, but the underlying mechanisms are not fully clear. Now, researchers at...
INDIANAPOLIS — Indiana University researchers are collaborating on a novel approach to use neuroimaging and network modeling tools—previously developed to analyze brains of patients in the clinic—to investigate Alzheimer’s disease progression in preclinical animal models. The research team, led by Evgeny Chumin, PhD, a postdoctoral research fellow in the College of...
INDIANAPOLIS, USA – Indiana University School of Medicine researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with Duchenne muscular dystrophy (DMD). The study, recently published in Nature Communications, demonstrates the effectiveness of their novel gene therapy technology in improving muscle tissue and overall strength in mice models with Duchenne muscular dystrophy. Duchenne muscular dystrophy is...
WASHINGTON – A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one’s risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general...
WASHINGTON – Individuals living with severe sickle cell disease (SCD) are highly interested in new, potentially curative gene therapy treatments and are willing to accept associated risks for a chance at a cure, according to a study published today in Blood Advances. SCD is an inherited red blood cell disorder...
Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand...